stockrow
Monday 9 November 2026
Export ACIU’s income statement to Excel — free account
AC Immune
ACIUAC Immune’s revenue for fiscal 2025 (year ended December 2025) was $4.3 million, down 86.1% from fiscal 2024.
- Revenue
- +152.3%
- EPS
- +36.0%
- Free cash flow
- +4.66%
Quarter to September 2026, against a year earlier
2.23
0.12
+5.69%
Follow ACIU
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | — | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
25.01 | — | 58.49 | 73.36 | |
P/FCF ratio |
0.00 | — | 0.00 | 0.00 | |
P/Operating CF |
(8.91) | — | (15.35) | (17.89) | |
P/B ratio |
5.32 | — | 6.74 | 5.84 | |
Price to Tangible BV |
0.00 | — | 0.00 | 0.00 | |
EV/Sales |
12.78 | — | 38.95 | 48.34 | |
EV/EBITDA |
0.00 | — | 0.00 | 0.00 | |
EV/Operating CF |
(1.09) | — | (2.16) | (2.49) | |
EV/FCF |
(1.08) | — | (2.13) | (2.46) | |
Quick Ratio |
0.80 | 0.89 | 0.82 | 0.98 | |
Current Ratio |
0.85 | 0.93 | 0.87 | 1.02 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 6.23 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.11 | 0.00 | |
Asset Turnover |
0.04 | 0.00 | 0.04 | 0.02 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.96 | |
Capex/Depreciation |
— | (0.42) | — | (0.13) | |
Interest Coverage |
(166.23) | — | (227.64) | (351.49) | |
Research and Development Expense of Revenue |
303.73% | — | 1,049.47% | 3,008.27% | |
Selling, General and Administrative Expense of Revenue |
108.57% | — | 373.00% | 1,165.84% | |
Intangible Assets out of Total Assets |
0.36 | 0.34 | 0.00 | 0.33 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 207.23% | |
Graham Net Nets |
(0.21) | — | (0.12) | (0.05) | |
Graham Number |
0.00 | — | 0.00 | 0.00 | |
Earnings Yield |
(27.87%) | — | (29.82%) | (26.75%) | |
Free Cash Flow Yield |
(47.45%) | — | (31.20%) | (26.76%) | |
Revenue per Share |
0.06 | — | 0.01 | 0.00 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | (0.18) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | (0.18) | |
Cash per Share |
1.35 | 0.00 | 0.97 | 1.10 | |
Shareholders Equity per Share |
0.49 | 0.00 | 0.41 | 0.54 | |
Interest Debt per Share |
0.00 | — | 0.00 | 0.00 | |
Book value per Share |
0.49 | 0.00 | 0.41 | 0.54 | |
Free Cash Flow |
— | (20.34) | — | (17.78) | |
Working Capital |
(18.54) | (8.65) | (15.56) | 2.45 | |
Capital Expenditures |
— | (0.54) | — | (0.10) | |
Net Current Asset Value |
(36.52) | (27.62) | (32.97) | (15.26) | |
EV/EBIT |
0.00 | — | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.21 | |
Price to Operating Income |
0.00 | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
3.39 | 9.48 | 1.92 | 1.22 | |
Average Payables |
1.49 | 2.61 | 2.17 | 2.76 | |
Average Assets |
201.00 | 212.56 | 117.40 | 224.24 | |
Average Common Equity |
55.60 | 67.55 | 72.85 | 90.85 |
Columns are period end dates · fundamentals updated 6 Nov 2026